CORT — CORCEPT THERAPEUTICS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1088856 ·
Last close
$70.07
Market Cap
$7.67B
52W High
$126.38
52W Low
$28.66
ADV30
1,107,478
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 340,472,000 335,864,000 114,724,000 126,778,000 1,034,027,000 98,720,000 200,287,000
Jun 2026 256,147,000 252,086,000 41,300,000 42,987,000 888,702,000 111,039,000 182,926,000
Mar 2026 164,903,000 162,020,000 -49,601,000 -31,761,000 814,881,000 108,738,000 176,894,000
Dec 2025 202,125,000 199,580,000 4,487,000 24,288,000 836,651,000 120,495,000 188,846,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$198,110,000
Investing CF
$-168,529,000
Financing CF
$-56,378,000
CapEx
$-3,488,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.27
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$781,391,000
Inventory
$11,907,000
Receivables
$111,061,000
ST Investments
$271,983,000
EBIT TTM
$110,910,000
Pretax Income TTM
$131,433,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$963,646,976
EBITDA
$113,138,000
Free Cash Flow
$132,181,752
Enterprise Value
$7,602,463,232
Total Cash
$370,703,008
Total Debt
$8,991,000
Shares Out
109,443,109
Trailing EPS
$1.33
Book Value
$7.62
ROE
22.1%
ROA
7.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 761,407,000 44,797,000 99,652,000 836,651,000 188,846,000 647,805,000 141,996,000
Dec 2024 675,040,000 136,951,000 141,209,000 840,553,000 160,964,000 679,589,000 198,295,000
Dec 2023 482,375,000 107,282,000 106,140,000 621,517,000 114,812,000 506,705,000 126,681,000
Dec 2022 401,858,000 112,634,000 101,418,000 583,430,000 81,588,000 501,842,000 120,323,000

TTM Snapshot

Revenues TTM
$830,813,000
NetIncome TTM
$55,182,000
OpCashFlow TTM
—
Assets (Latest)
$888,702,000
Forward EPS
$4.22

Max Pain — expiry 2026-12-18

max pain strike: $85.00 · spot: $67.79 · call oi: 4,183 · put oi: 6,997
Expected Move to 2026-12-18: ±$14.80 (21.83%) — implied range $52.99 – $82.59 · ATM straddle on $70.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALKS Alkermes plc. $7.64B $45.45 —
AMRX Amneal Pharmaceuticals, Inc. $7.36B $21.12 —
PTGX Protagonist Therapeutics, Inc $8.07B $124.67 —
RYTM RHYTHM PHARMACEUTICALS, INC. $8.08B $116.61 —
CYTK CYTOKINETICS INC $7.20B $51.65 —

News headlines (Yahoo Finance, 1h cache)

What Is Driving The Move In Corcept Therapeutics Stock?
2026-11-18 11:29 · Yahoo
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
2026-11-16 13:00 · Yahoo
Can You Justify Buying Corcept Stock Today?
2026-11-06 12:20 · Yahoo
Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build
2026-11-06 06:13 · Yahoo
Corcept Therapeutics Incorporated Q3 2026 Earnings Call Summary
2026-11-05 01:42 · Yahoo
Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...
2026-11-04 19:05 · Yahoo
Corcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript
2026-11-04 15:45 · Yahoo
Corcept Therapeutics Q3 Earnings Call Highlights
2026-11-04 00:14 · Yahoo
Corcept Therapeutics falls on guidance despite earnings beat
2026-11-03 22:20 · Yahoo
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
2026-11-03 21:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.